MX2021006147A - Nuevo cristal de (3s)-3-[2-(6-amino-2-fluoropiridin-3-il)-4-fluoro -1h-imidazol-5-il]-7-[5-cloro-2-(1h-tetrazol-1-il)fenil]-2,3-dihi droindolizin-5(1h)-ona. - Google Patents

Nuevo cristal de (3s)-3-[2-(6-amino-2-fluoropiridin-3-il)-4-fluoro -1h-imidazol-5-il]-7-[5-cloro-2-(1h-tetrazol-1-il)fenil]-2,3-dihi droindolizin-5(1h)-ona.

Info

Publication number
MX2021006147A
MX2021006147A MX2021006147A MX2021006147A MX2021006147A MX 2021006147 A MX2021006147 A MX 2021006147A MX 2021006147 A MX2021006147 A MX 2021006147A MX 2021006147 A MX2021006147 A MX 2021006147A MX 2021006147 A MX2021006147 A MX 2021006147A
Authority
MX
Mexico
Prior art keywords
fluoropyridine
tetrazole
imidazole
chloro
phenyl
Prior art date
Application number
MX2021006147A
Other languages
English (en)
Inventor
Shizuka Ono
Takayuki Fujito
Shuhei Ohtani
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2021006147A publication Critical patent/MX2021006147A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona una nueva forma cristalina de la (3S)-3-[2-(6-amino-2-fluoropiridin-3-il)-4-fluoro-1H-imidazol-5-i l]-7-[5-cloro-2-(1H-tetrazol-1-il)fenil]-2,3-dihidroindolizin-5(1 H)-ona. Se proporciona el ácido (3S)-3-[2-(6-amino-2-fluoropiridin -3-il)-4-fluoro-1H-imidazol-5-il]-7-[5-cloro-2-(1H-tetrazol-1-il) fenil]-2,3-dihidroindolizin-5(1H)-ona-3-hidroxibenzoico (1/1).
MX2021006147A 2018-11-30 2019-11-29 Nuevo cristal de (3s)-3-[2-(6-amino-2-fluoropiridin-3-il)-4-fluoro -1h-imidazol-5-il]-7-[5-cloro-2-(1h-tetrazol-1-il)fenil]-2,3-dihi droindolizin-5(1h)-ona. MX2021006147A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018224434 2018-11-30
PCT/JP2019/046893 WO2020111268A1 (ja) 2018-11-30 2019-11-29 （３ｓ）－３－［２－（６－アミノ－２－フルオロピリジン－３－イル）－４－フルオロ－１ｈ－イミダゾール－５－イル］－７－［５－クロロ－２－（１ｈ－テトラゾール－１－イル）フェニル］－２，３－ジヒドロインドリジン－５（１ｈ）－オンの新規結晶

Publications (1)

Publication Number Publication Date
MX2021006147A true MX2021006147A (es) 2021-06-23

Family

ID=70853323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006147A MX2021006147A (es) 2018-11-30 2019-11-29 Nuevo cristal de (3s)-3-[2-(6-amino-2-fluoropiridin-3-il)-4-fluoro -1h-imidazol-5-il]-7-[5-cloro-2-(1h-tetrazol-1-il)fenil]-2,3-dihi droindolizin-5(1h)-ona.

Country Status (15)

Country Link
US (1) US20210395250A1 (es)
EP (1) EP3888653A4 (es)
JP (1) JP7196931B2 (es)
KR (1) KR20210097119A (es)
CN (1) CN113226312A (es)
AU (1) AU2019390094A1 (es)
BR (1) BR112021010476A2 (es)
CA (1) CA3121447A1 (es)
IL (1) IL283481A (es)
MX (1) MX2021006147A (es)
PH (1) PH12021551219A1 (es)
SG (1) SG11202105697SA (es)
TW (1) TWI826599B (es)
WO (1) WO2020111268A1 (es)
ZA (1) ZA202103692B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022125869A1 (en) * 2020-12-11 2022-06-16 Board Of Regents, The University Of Texas System Compositions and methods of making cocrystals using dielectric heating with dispersive and distributive mixing
WO2023002984A1 (ja) * 2021-07-20 2023-01-26 小野薬品工業株式会社 イミダゾール化合物の製造方法
TWI833610B (zh) * 2022-03-21 2024-02-21 大陸商上海濟煜醫藥科技有限公司 三并環類化合物製備方法及其中間體

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2765891T3 (es) 2011-12-21 2020-06-11 Ono Pharmaceutical Co Derivados de piridinona y pirimidinona como inhibidores del factor XIa
JP2016093285A (ja) 2014-11-13 2016-05-26 株式会社ユニバーサルエンターテインメント 遊技機
BR112017012146B1 (pt) 2014-12-10 2023-11-21 Ono Pharmaceutical Co., Ltd Composto derivado de di-hidroindolizinona, seu uso, composição farmacêutica e inibidor de fxia
JP6992284B2 (ja) * 2016-06-06 2022-01-13 小野薬品工業株式会社 ジヒドロインドリジノン誘導体を含有する医薬組成物

Also Published As

Publication number Publication date
US20210395250A1 (en) 2021-12-23
JPWO2020111268A1 (ja) 2021-10-14
PH12021551219A1 (en) 2021-11-08
BR112021010476A2 (pt) 2021-08-24
KR20210097119A (ko) 2021-08-06
EP3888653A4 (en) 2022-08-24
WO2020111268A1 (ja) 2020-06-04
CN113226312A (zh) 2021-08-06
TWI826599B (zh) 2023-12-21
IL283481A (en) 2021-07-29
ZA202103692B (en) 2023-03-29
SG11202105697SA (en) 2021-06-29
TW202039485A (zh) 2020-11-01
AU2019390094A1 (en) 2021-06-17
JP7196931B2 (ja) 2022-12-27
CA3121447A1 (en) 2020-06-04
EP3888653A1 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
PH12021551219A1 (en) Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1himidazol- 5-yl]-7-[5-chloro-2-(1h-tetrazol-1-yl)phenyl]-2,3- dihydroindolizin-5(1h)-one
PH12017500361B1 (en) Novel compounds
CY1118621T1 (el) Πολυμορφικες μορφες του 2-(5-βρωμο-4-(4-κυκλο προπυλναφθαλιν-1-υλ)-4η-1,2,4-τριαζολ-3-υλθειο) οξικου οξεος και χρησεις αυτων
IL290965A (en) Converted pyridopyrimidinonyl compounds for use as t-cell activators
EP3877779A4 (en) INTEGRATED COOLING SOLUTION FOR SPIDER SENSORS
EA201270676A1 (ru) Полиморфная, кристаллическая и мезофазная формы 2-(5-бром-4-(4-циклопропилнафталинил-1-ил)-4н-1,2,4-триазол-3- илтио)ацетата натрия и их применение
EA201891768A1 (ru) Кристаллическая форма a агониста tlr7, ее способ получения и использование
MA53605A (fr) Composés d'isoxazoline pour lutter contre des invertébrés nuisibles
PH12015500009B1 (en) Phenoxyethyl piperidine compounds
PH12014502210A1 (en) Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
EP4066893A4 (en) HETEROCYCLIC COMPOUND
EP3935037A4 (en) USE OF 8,9-DIHYDROCANNABIDIOL COMPOUNDS
EP3985005A4 (en) FUSED RING COMPOUND AS DUAL FGFR AND VEGFR INHIBITOR
MA54239A (fr) Bioréacteurs pour la culture de micro-organismes
EP4006037A4 (en) HETEROCYCLIC COMPOUND
WO2017094031A3 (en) Novel process for preparation of apremilast
EP3836928A4 (en) NOVEL SUBSTITUTED TETRAHYDROCHINOLINE COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS
EP3781569A4 (en) CRYSTALLINE FORMS OF A COMPOUND
CO2018000953A2 (es) Asociación entre la 3 - [(3 - {[4- (4-morfolinilmetil) -1h-pirrol-2-il] metilen} -2-oxo-2,3-dihidro-1h-indol-5-il) metil ] -1,3-tiazolidina-2,4-diona y un inhibidor de la tyr quinasa del egfr
EP3978485A4 (en) NOVEL CRYSTAL FORM OF 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOYNIC ACID DERIVATIVE
IL287230A (en) A process for the production of modified 2-[2-(phenyl)ethylamino]alkanamide derivatives
IL287228A (en) A process for producing modified 2-[2-(phenyl)ethylamino]alkanamide derivatives
MX2013012457A (es) Derivados heteroaromaticos de anillo de 5 miembros que tienen actividad antagonista del receptor y5 de neuropeptido (npy).
AU2021904153A0 (en) Crystalline Intermediates
EP3980406A4 (en) Heterocyclic compounds